These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1801560)

  • 41. Retrospective study of the course, treatment and long-term follow-up of Kawasaki disease: a single-center experience from Poland.
    Stasiak A; Smolewska E
    Rheumatol Int; 2019 Jun; 39(6):1069-1076. PubMed ID: 30903369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of giant coronary artery aneurysms in Kawasaki disease by intravenous gamma globulin therapy.
    Rowley AH; Duffy CE; Shulman ST
    J Pediatr; 1988 Aug; 113(2):290-4. PubMed ID: 2456378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The occurrence of coronary artery lesions in Kawasaki disease based on C-reactive protein levels: a retrospective cohort study.
    An HS; Kim GB; Song MK; Lee SY; Kwon HW; Lee JW; Bae EJ
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):78. PubMed ID: 34078404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
    J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Muta H; Ishii M; Egami K; Furui J; Sugahara Y; Akagi T; Nakamura Y; Yanagawa H; Matsuishi T
    J Pediatr; 2004 Apr; 144(4):496-9. PubMed ID: 15069399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognosis of coronary arterial lesions in Kawasaki disease treated without intravenous immunoglobulin.
    Tzen KT; Wu MH; Wang JK; Lue HC; Lee CY; Chien SC
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1997; 38(1):32-7. PubMed ID: 9066187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effective use of echocardiography in children with Kawasaki disease.
    Scott JS; Ettedgui JA; Neches WH
    Pediatrics; 1999 Nov; 104(5):e57. PubMed ID: 10545583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Giant coronary aneurysms due to Kawasaki disease: a case-control study.
    Nakamura Y; Yashiro M; Oki I; Tanihara S; Ojima T; Yanagawa H
    Pediatr Int; 2002 Jun; 44(3):254-8. PubMed ID: 11982891
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting coronary aneurysms in Kawasaki disease.
    Gersony WM
    Am J Cardiol; 1998 May; 81(9):1162-4. PubMed ID: 9605060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Six Kawasaki disease patients with acute coronary artery thrombosis].
    Zhou SL; Luo JP; Qi YQ; Liang YG; Wang W; Gong FQ
    Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):925-9. PubMed ID: 24495764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
    Downie ML; Manlhiot C; Collins TH; Chahal N; Yeung RSM; McCrindle BW
    Int J Cardiol; 2017 Jun; 236():157-161. PubMed ID: 28089146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term outcome of coronary abnormalities in patients after Kawasaki disease.
    Fukushige J; Takahashi N; Ueda K; Hijii T; Igarashi H; Ohshima A
    Pediatr Cardiol; 1996; 17(2):71-6. PubMed ID: 8833489
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitory effects of high doses of intravenous gamma-globulin on platelet interaction with the vessel wall in Kawasaki disease.
    Inagaki M; Yamada K
    Acta Paediatr Jpn; 1991 Dec; 33(6):791-8. PubMed ID: 1801559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The immunologic effects of IVIG in Kawasaki disease.
    Leung DY
    Int Rev Immunol; 1989; 5(2):197-202. PubMed ID: 8691053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative safety and efficacy of two immune globulin products in Kawasaki disease.
    Rosenfeld EA; Shulman ST; Corydon KE; Mason W; Takahashi M; Kuroda C
    J Pediatr; 1995 Jun; 126(6):1000-3. PubMed ID: 7776074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
    Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation of unresponsiveness to standard high-dose gamma globulin therapy in Kawasaki disease].
    Tavli V; Yilmazer MM; Güven B; Meşe T; Oner T; Demirpençe S
    Turk Kardiyol Dern Ars; 2010 Jan; 38(1):20-4. PubMed ID: 20215838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of pharmacological treatment of Kawasaki disease.
    Onouchi Z; Kawasaki T
    Drugs; 1999 Nov; 58(5):813-22. PubMed ID: 10595862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
    Dhanrajani A; Chan M; Pau S; Ellsworth J; Petty R; Guzman J
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1536-1540. PubMed ID: 29287309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neutropenia after intravenous immunoglobulin therapy is associated with coronary artery lesions in children with Kawasaki disease: a case control study.
    Wang Z; Weng F; Li C; Shi H; Tang Z; Qiu H; He Y; Wu R; Chu M
    BMC Pediatr; 2018 Feb; 18(1):76. PubMed ID: 29466965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.